The company expects this technology to redefine stroke management by enabling more precise clot capture, ultimately improving patient recovery trajectories. Shruthi Narayan, president of Penumbra, described the approval as the start of a new era for clinical outcomes in stroke care. Each Thunderbolt unit will ship prepackaged with one of the company's proprietary catheters to streamline surgical workflows.
In section Market Quotes
Penumbra Secures FDA Nod for Thunderbolt Stroke Treatment
With global stroke mortality projected to climb 50% by 2050, Penumbra has received FDA clearance for its Thunderbolt system. The device utilizes computer-assisted vacuum thrombectomy to identify and remove blood clots, aiming to restore cerebral blood flow while minimizing the invasive catheter manipulation typically required during neurovascular procedures.
Following the announcement, shares of the medical-technology firm rose 3.3% in after-hours trading. The company is positioning the product as a critical intervention for acute ischemic stroke, currently the second leading cause of death worldwide.
Comments (0)
No comments yet. Be the first!